Clinical Intelligence

FDA approves clinical trial of artificial pancreas

Monday, March 19, 2012 03:46 PM

The FDA has approved the first outpatient artificial pancreas trial in the U.S., which will be funded by JDRF, a global organization focused on type 1 diabetes research.

More... »

Repligen enrolls first patient in phase I trial of Friedreich’s Ataxia

Monday, March 19, 2012 03:20 PM

Waltham, Mass.-based Repligen has enrolled the first patient in a phase I clinical trial of RG2833 in adult patients with Friedreich’s Ataxia (FA)—a debilitating, life-shortening, degenerative neuro-muscular disorder that currently has no treatment.

More... »

diaDexus highlights findings of two PLAC Lp-PLA(2) activity studies

Monday, March 19, 2012 11:49 AM

San Francisco–based diaDexus, a company focused on proprietary cardiovascular diagnostic products, reported highlights from two recent studies evaluating the clinical utility of its PLACR Test for Lp-PLA(2) activity.

More... »

Provectus reports top-line data in phase II psoriasis study

Monday, March 19, 2012 10:39 AM

Provectus Pharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, reported top-line data for the company's randomized controlled trial of PH-10, a topical aqueous hydrogel, for mild-to-moderate plaque psoriasis.

More... »

Omeros' OMS302 reduces pain and pupil dilation in lens replacement post-op

Friday, March 16, 2012 04:51 PM

Omeros has reported positive data from its phase III clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery.

More... »

Gintuit receives FDA approval for gum tissue regeneration

Thursday, March 15, 2012 06:00 AM

The FDA has approved Gintuit, a cell-based topical product that has been shown to predictably generate new and aesthetically appealing oral soft tissue, according to Organogenesis.

More... »

Creabilis begins phase IIb trial of CT327 in psoriasis

Wednesday, March 14, 2012 09:25 AM

Creabilis, a European biotechnology company specializing in dermatology, inflammation and pain, has initiated a phase IIb global clinical trial of its lead product CT327 in patients with psoriasis vulgaris.

More... »

Tranzyme, Norgine report endpoint failure for ulimorelin

Wednesday, March 14, 2012 09:24 AM

Tranzyme Pharma and Norgine BV, a European specialty pharmaceutical company, reported ULISES 007’s failure to meet its primary and secondary efficacy endpoints.

More... »

HemaQuest raises $13 million for phase IIb study of sickle cell disease

Monday, March 12, 2012 03:49 PM

HemaQuest Pharmaceuticals, a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, has closed a $13 million extension of its Series B financing.

More... »

Genticel completes recruitment for phase Ib HPV vaccine trial

Wednesday, March 7, 2012 06:15 AM

Genticel, a biopharmaceutical company based in Toulouse and Paris, France, has completed the recruitment of all patients participating in its phase Ib clinical trial evaluating a lyophilized formulation of ProCervix, its candidate therapeutic HPV vaccine, on adult women already infected with human papillomavirus (HPV) genotypes 16 or 18.

More... »